SPRINGWORKS THERAPEUTICS, INC. (SWTX): Price and Financial Metrics


SPRINGWORKS THERAPEUTICS, INC. (SWTX): $69.52

1.93 (+2.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SWTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

SWTX POWR Grades


  • Value is the dimension where SWTX ranks best; there it ranks ahead of 48.75% of US stocks.
  • SWTX's strongest trending metric is Growth; it's been moving down over the last 52 weeks.
  • SWTX ranks lowest in Momentum; there it ranks in the 8th percentile.

SWTX Stock Summary

  • SWTX's went public 2.22 years ago, making it older than just 5.39% of listed US stocks we're tracking.
  • SWTX's price/sales ratio is 95.11; that's higher than the P/S ratio of 96.75% of US stocks.
  • SWTX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.67% of US stocks.
  • Stocks that are quantitatively similar to SWTX, based on their financial statements, market capitalization, and price volatility, are ACRS, RESN, CUE, CCXI, and FREQ.
  • Visit SWTX's SEC page to see the company's official filings. To visit the company's web site, go to www.springworkstx.com.

SWTX Valuation Summary

  • SWTX's price/sales ratio is 105.4; this is 828.63% higher than that of the median Healthcare stock.
  • SWTX's price/earnings ratio has moved down 7.6 over the prior 24 months.
  • SWTX's price/earnings ratio has moved down 7.6 over the prior 24 months.

Below are key valuation metrics over time for SWTX.

Stock Date P/S P/B P/E EV/EBIT
SWTX 2021-08-31 105.4 7.4 -42.3 -41.4
SWTX 2021-08-30 107.7 7.6 -43.2 -42.3
SWTX 2021-08-27 111.0 7.8 -44.5 -43.6
SWTX 2021-08-26 107.4 7.6 -43.1 -42.1
SWTX 2021-08-25 110.9 7.8 -44.5 -43.6
SWTX 2021-08-24 107.8 7.6 -43.3 -42.3

SWTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SWTX has a Quality Grade of D, ranking ahead of 14.5% of graded US stocks.
  • SWTX's asset turnover comes in at 0.072 -- ranking 285th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SWTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.072 1 -0.239
2021-03-31 0.081 1 -0.217
2020-12-31 0.095 1 -0.275
2020-09-30 0.000 NA -1.198
2020-06-30 0.000 NA -5.408

SWTX Price Target

For more insight on analysts targets of SWTX, see our SWTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $114.80 Average Broker Recommendation 1.42 (Moderate Buy)

SWTX Stock Price Chart Interactive Chart >

Price chart for SWTX

SWTX Price/Volume Stats

Current price $69.52 52-week high $96.48
Prev. close $67.59 52-week low $51.72
Day low $67.00 Volume 25,859
Day high $69.64 Avg. volume 295,174
50-day MA $65.66 Dividend yield N/A
200-day MA $74.17 Market Cap 3.42B

SPRINGWORKS THERAPEUTICS, INC. (SWTX) Company Bio


Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.


SWTX Latest News Stream


Event/Time News Detail
Loading, please wait...

SWTX Latest Social Stream


Loading social stream, please wait...

View Full SWTX Social Stream

Latest SWTX News From Around the Web

Below are the latest news stories about SpringWorks Therapeutics Inc that investors may wish to consider to help them evaluate SWTX as an investment opportunity.

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

STAMFORD, Conn., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has achieved full enrollment in its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with NF1-associated plexiform neurofibromas (NF1-PN). The study enrolled over 50 adults an

Yahoo | November 29, 2021

SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

STAMFORD, Conn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, November 30, 2021, at 3:30 pm ET. A video webcast will be available on the Events & Presentations page wi

Yahoo | November 23, 2021

SpringWorks Therapeutics (NASDAQ:SWTX) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of SpringWorks Therapeutics (NASDAQ:SWTX) from a sell rating to a hold rating in a report released on Friday morning, Zacks.com reports. According to Zacks, SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The companys product []

Dakota Financial News | November 16, 2021

Charles Schwab Investment Management Inc. Has $15.92 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Charles Schwab Investment Management Inc. raised its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 7.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 193,144 shares of the companys stock after purchasing an additional 13,358 shares during the period. Charles Schwab []

Dakota Financial News | November 14, 2021

Boothbay Fund Management LLC Acquires New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Boothbay Fund Management LLC acquired a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,799 shares of the companys stock, valued at approximately $231,000. Several other institutional investors have also added to or reduced []

Transcript Daily | November 13, 2021

Read More 'SWTX' Stories Here

SWTX Price Returns

1-mo 3.67%
3-mo -8.89%
6-mo -9.34%
1-year 6.23%
3-year N/A
5-year N/A
YTD -4.14%
2020 88.41%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6985 seconds.